Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Recently, Shanghai Resthetic Biotech Co. Ltd. (hereinafter referred to as "Resthetic Bio") announced the completion of a nearly 100-million-yuan Pre-A round of financing, led by Ruili Capital and Nuoyu Capital.The funds from this financing will be used to accelerate the advancement of tissue-engineered bone and cartilage regeneration technology into clinically promotable technologies and product stages, laying a solid foundation of technical and clinical data for registration clinical trials, further consolidating Resthetic Bio's leading position in the field of tissue engineering.
Ruide Capital stated：Resthetic Bio is a leading enterprise in the field of regenerative medicine in China. The company's innovative technology focuses on the repair of refractory tissue defects, breaking through the clinical limitations of traditional treatment methods and filling the gaps in niche areas of regenerative medicine. Its differentiated innovation path and clinical advantages highlight significant scarcity value. We are optimistic about the company’s complete innovation chain that integrates industry, academia, research, and medicine, and firmly believe that this chain can efficiently transform "laboratory technology" into "clinically accessible treatment solutions," lighting up the hope of "autologous regeneration" for more patients. Ruili Capital will fully support the company’s accelerated development, helping it further consolidate its leading position in the industry, promote high-quality development of China’s regenerative medicine industry, and inject new momentum into the innovation of the healthcare industry.Noyu Capital stated:The value of Resthetic Bio lies not only in its breakthrough solutions for specific indications but also in its establishment of an underlying model with highly scalable platform capabilities and technology-driven growth. It has paved an efficient and compliant dual pathway for the commercialization of technology, significantly reducing the conversion risk from technology to market. We look forward to partnering with the company to promote its innovative achievements in benefiting a broader patient population and leading the overall development of China's tissue engineering industry.Resthetic Bio was founded in November 2017 and is located in Shanghai Zizhu Science Park.Committed to innovative technologies in the field of cell and tissue engineering, addressing the core clinical challenge of tissue and organ loss and functional impairment. As a cutting-edge discipline in biomedical engineering, tissue engineering technology is regarded as a crucial component of the "third medical revolution" following drug therapy and surgical treatment. ItsThe basic principle is to obtain a small amount of autologous cells (such as stem cells, bone marrow fluid, or ear cartilage, etc.) from the patient's body.After amplification and culture in vitro, the cells are combined with degradable biological scaffold materials to construct bioactive tissues, which are ultimately implanted into the human body to achieve "living tissue regeneration." This technical approach not only avoids the trauma associated with traditional autologous transplantation, often described as "robbing Peter to pay Paul," but also completely eliminates the risks of rejection and infection that may be caused by artificial materials.
In terms of clinical translation, Resthetic Bio has made substantial progress. The company has currently developed three product pipelines targeting bone and cartilage defect repair, and has collaborated with several well-known tertiary hospitals to conduct more than 10 exploratory clinical studies, accumulating over 200 clinical cases. Among these, two projects—"Autologous Tissue-Engineered Bone Transplant for Nasal Turbinate Reconstruction" and "Tissue-Engineered Cartilage for Cleft Lip and Palate Nasal Deformity Correction"—have received stem cell clinical research registration from the National Health Commission. These technologies have achieved critical breakthroughs in areas where traditional treatments have significant shortcomings, such as Empty Nose Syndrome and cleft lip nasal deformities. Follow-up data shows that the implanted tissue-engineered bone and cartilage can survive stably over the long term, with remarkable clinical outcomes.According to reports, with the completion of this round of financing, Resthetic Bio will further accelerate the advancement of multi-center clinical trials. The company will rely on relevant policies such as Decree No. 818 of the State Council, and through multi-center clinical research, cultivate leading hospitals and doctor teams in each province. It will actively promote the application and transformation of technological achievements, striving to bring this innovative regenerative medicine solution to a broader market as soon as possible, benefiting more patients.References:
Public Information
Mastering CAR-T Therapy, Stem Cell Therapy, GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
